MetaVia Inc（MTVA）资讯与事件MTVAMetaVia Inc

MetaVia's DA-1726 Clinical Trial Shows 68% Reduction in Liver Fat

MetaVia announced positive interim data from Part 3B of its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin analog targeting both GLP-1 and glucagon receptors. The results, presented in an oral presentation at the Precision Liver Symposium on November 4, 2026, in Denver, Colorado, demonstrated a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted body weight reduction following 16 weeks of once-weekly DA-1726 treatment in otherwise healthy adults with obesity. At Day 109, 10 of 12 DA-1726-treated participants (83%) in the MRI substudy achieved a relative liver fat reduction of at least 30%, compared with none on placebo. All DA-1726-treated participants with baseline liver steatosis achieved MRI-PDFF below 5%. DA-1726 also lowered HbA1c from 5.79% at baseline to 5.33% at Day 109, a 0.24 percentage-point placebo-adjusted reduction in participants who were not diabetic at entry, with significant reductions in adipose tissue and relative preservation of lean tissue and muscle volume. "These are the most compelling clinical data we have generated to date supporting DA-1726's potential as a liver-focused cardiometabolic therapy," said Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "A 68% placebo-adjusted reduction in liver fat after approximately 16 weeks, together with all five participants who entered the study with liver steatosis achieving MRI-PDFF below 5%, provides a strong clinical rationale for expanding DA-1726 into liver disease. Importantly, these liver findings were accompanied by 13.5% placebo-adjusted weight loss, improvements in HbA1c, and significant reductions across visceral and subcutaneous adipose tissue, while lean tissue and muscle volume were relatively preserved."

MetaVia Appoints Sarah Browne as Chief Medical Officer

MetaVia announced the appointment of Sarah Browne, M.D., as Chief Medical Officer, effective October 12. Dr. Browne brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, with particular expertise in liver and metabolic diseases, including metabolic dysfunction-associated steatohepatitis. Dr. Browne most recently served as a Clinical Development Consultant to Souffle Therapeutics, where she supported clinical development planning and regulatory strategy.

MetaVia Announces DA-1726 Preclinical Study Results

MetaVia announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body following subcutaneous administration, with broad tissue distribution and the highest tissue exposure observed in adipose tissue. Data from the study showed that tissue-to-plasma ratios increased over time, indicating prolonged retention of DA-1726-derived radioactivity in tissues relative to plasma. Consistent with this finding, the greatest exposure outside of the injection site occurred in abdominal, subcutaneous and brown fat, as well as the liver. The preclinical study data also demonstrated prolonged retention of DA-1726-derived radioactivity in tissues through the final 144-hour assessment, consistent with the prolonged pharmacokinetic profile supporting once-weekly dosing of DA-1726. In addition, only minimal radioactivity was detected in the central nervous system, consistent with the limited brain penetration typically observed with peptide-based therapies. DA-1726 is a novel GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors and glucagon receptors, leading to weight loss through reduced appetite and increased energy expenditure.